Abstract
We describe here the Oncobox method for scoring efficiencies of anticancer target drugs (ATDs) using high throughput gene expression data. The method rationale, design, and validation are given along with the examples of its practical applications in biomedicine. The method is based on the analysis of intracellular molecular pathways activation and measuring expressions of molecular target genes for every ATD under consideration. Using Oncobox method requires collection of normal (control) expression profiles and annotated databases of molecular pathways and drug target genes. Both microarray and RNA sequencing profiles are acceptable, although the latter type of data prevails in the most recent applications of this technique.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ATD:
-
Anticancer target drug
- IMP:
-
Intracellular molecular pathway
- NGS:
-
Next generation sequencing
- PAL:
-
Pathway activation level, calculated using mRNA or protein expression data
References
Hanna N, Einhorn LH (2014) Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol 32:3085–3092
Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T et al (2015) Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol 26:833–838
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L et al (2005) Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 23:4399–4405
Kayl AE, Meyers CA (2006) Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol 18:24–28
Buzdin A, Sorokin M, Garazha A, Sekacheva M, Kim E, Zhukov N et al (2018) Molecular pathway activation – new type of biomarkers for tumor morphology and personalized selection of target drugs. Semin Cancer Biol 53:110–124
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Spirin P, Lebedev T, Orlova N, Morozov A, Poymenova N, Dmitriev SE et al (2017) Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors. Oncotarget 8:56991–57002
Sjöström J (2002) Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 41:334–345
Aggarwal S (2010) Targeted cancer therapies. Nat Rev Drug Discov 9:427–428
Hudis CA (2007) Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 357:39–51
Nahta R, Esteva FJ (2007) Trastuzumab: triumphs and tribulations. Oncogene 26:3637–3643
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4–13
Institute for Quality and Efficiency in Health Care (2014) Curation vs. palliation: an attempt to clarify terms. Institute for Quality and Efficiency in Health Care (IQWiG), Cologne
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 71:249–257
Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313–324
Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T et al (2014) Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br J Cancer 111:17–24
Martel CL, Lara PN (2003) Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 45:177–190
Poole RM (2014) Pembrolizumab: first global approval. Drugs 74:1973–1981
Russell K, Shunyakov L, Dicke KA, Maney T, Voss A (2014) A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service. Front Pharmacol 5:76
Green DE, Jayakrishnan TT, Hwang M, Pappas SG, Gamblin TC, Turaga KK (2014) Immunohistochemistry - microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin. Front Surg 1:50
Popovtzer A, Sarfaty M, Limon D, Marshack G, Perlow E, Dvir A et al (2015) Metastatic salivary gland tumors: a single-center study demonstrating the feasibility and potential clinical benefit of molecular-profiling-guided therapy. Biomed Res Int 2015:614845
Vigneswaran J, Tan Y-HC, Murgu SD, Won BM, Patton KA, Villaflor VM et al (2016) Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget 7:18876–18886
Blagosklonny MV (2013) MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. Cell Cycle 12:1842–1847
Borisov N, Sorokin M, Garazha AV, Buzdin A (2019) Quantitation of molecular pathway activation using RNA sequencing data. In: Walker J (ed) Methods Molecular Biology. Springer, Heidelberg
Zolotovskaia M, Sorokin M, Garazha A, Borisov N, Buzdin A (2019) Molecular pathway analysis of mutation data for biomarkers discovery and scoring of target cancer drugs. In: Walker J (ed) Methods Molecular Biology. Springer, Heidelberg
Borisov N, Suntsova M, Sorokin M, Garazha A, Kovalchuk O, Aliper A et al (2017) Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data. Cell Cycle 16:1810–1823
Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS et al (2014) The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Front Mol Biosci 1:8
Artemov A, Aliper A, Korzinkin M, Lezhnina K, Jellen L, Zhukov N et al (2015) A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. Oncotarget 6:29347–29356
Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA et al (2015) Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Hum Genome Var 2:15009
Venkova L, Aliper A, Suntsova M, Kholodenko R, Shepelin D, Borisov N et al (2015) Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs. Oncotarget 6:27227–27238
Buzdin AA, Prassolov V, Zhavoronkov AA, Borisov NM (2017) Bioinformatics meets biomedicine: OncoFinder, a quantitative approach for interrogating molecular pathways using gene expression data. Methods Mol Biol 1613:53–83
Buzdin A, Sorokin M, Glusker A, Garazha A, Poddubskaya E, Shirokorad V et al (2017) Activation of intracellular signaling pathways as a new type of biomarkers for selection of target anticancer drugs. J Clin Oncol 35:e23142–e23142
Zolotovskaia MA, Sorokin MI, Roumiantsev SA, Borisov NM, Buzdin AA (2018) Pathway instability is an effective new mutation-based type of cancer biomarkers. Front Oncol 8:658
Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G et al (2014) The Reactome pathway knowledgebase. Nucleic Acids Res 42:D472–D477
Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T et al (2009) PID: the pathway interaction database. Nucleic Acids Res 37:D674–D679
Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30
Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD (2005) Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 6:R2
Nishimura D (2001) BioCarta. Biotech Software Internet Rep 2:117–120
Borisov N, Shabalina I, Tkachev V, Sorokin M, Garazha A, Pulin A et al (2019) Shambhala: a platform-agnostic data harmonizer for gene expression data. BMC Bioinformatics 20:66
Rudy J, Valafar F (2011) Empirical comparison of cross-platform normalization methods for gene expression data. BMC Bioinformatics 12:467
Zolotovskaia MA, Sorokin MI, Emelianova AA, Borisov NM, Kuzmin DV, Borger P et al (2019) Pathway based analysis of mutation data is efficient for scoring target cancer drugs. Front Pharmacol 10:1
Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y et al (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42:D1091–D1097
Lamb J (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935
Wilkinson L (2011) ggplot2: elegant graphics for data analysis by WICKHAM, H. Biometrics 67:678–679
Poddubskaya EV, Baranova MP, Allina DO, Smirnov PY, Albert EA, Kirilchev AP et al (2018) Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Exp Hematol Oncol 7:21
Borisov N, Buzdin AA, Zavoronkovs A, Aliper AM, Allina D, Kovalchuk O et al (2017) System, method, and software for improved drug efficacy and safety in a patient. US Patent US20170193176A1
Borisov N, Tkachev V, Suntsova M, Kovalchuk O, Zhavoronkov A, Muchnik I et al (2018) A method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency. Cell Cycle 17:486–491
Borisov N, Tkachev V, Buzdin A, Muchnik I (2018) Prediction of drug efficiency by transferring gene expression data from cell lines to cancer patients. In: Rozonoer L, Mirkin B, Muchnik I (eds) Braverman readings in machine learning. Key ideas from inception to current state. Springer, Cham, pp 201–212
Borisov N, Tkachev V, Muchnik I, Buzdin A (2017) Individual drug treatment prediction in oncology based on machine learning using cell culture gene expression data. ACM Press, New York, NY, pp 1–6
Poddubskaya E, Baranova M, Allina D, Sekacheva M, Makovskaia L, Kamashev D et al (2019) Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. Cold Spring Harb Mol Case Stud. https://doi.org/10.1101/mcs.a003434
Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S (2018) Cancer stem cell metabolism and potential therapeutic targets. Front Oncol 8:203
Zhang L, Zhang H, Ai H, Hu H, Li S, Zhao J et al (2018) Applications of machine learning methods in drug toxicity prediction. Curr Top Med Chem 18:987–997
Acknowledgments
This study was supported by the Russian Science Foundation grant 18-15-00061.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Tkachev, V., Sorokin, M., Garazha, A., Borisov, N., Buzdin, A. (2020). Oncobox Method for Scoring Efficiencies of Anticancer Drugs Based on Gene Expression Data. In: Astakhova, K., Bukhari, S. (eds) Nucleic Acid Detection and Structural Investigations. Methods in Molecular Biology, vol 2063. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0138-9_17
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0138-9_17
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0137-2
Online ISBN: 978-1-0716-0138-9
eBook Packages: Springer Protocols